Tag: sickle cell disease

January 30, 2019

GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell...
December 3, 2018

GBT Announces Positive 24-week Results from Phase 3 HOPE Study

Global Blood Therapeutics (Nasdaq:GBT) today announced updated efficacy and safety results from Part A of its Phase 3 HOPE Study...
February 28, 2018

GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results

Global Blood Therapeutics (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the fourth quarter and year ended December...
December 7, 2017

CRISPR Therapeutics Submits Clinical Trial Application for a CRISPR Gene-Edited Therapy

CRISPR Therapeutics announced the submission of a clinical trial application for CTX001 in β-thalassemia.
January 18, 2017

Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) today announced enrollment of the first patient in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit...
November 28, 2016

Global Blood Therapeutics Announces Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary Fibrosis (IPF)

Global Blood Therapeutics today announced enrollment of the first patient in ZEPHYR, a Phase 2a clinical trial evaluating the safety...
November 21, 2016

Novartis Acquires Selexys Pharmaceuticals

Novartis announced today that it has acquired Selexys Pharmaceuticals, which specializes in developing treatments for select hematologic and inflammatory disorders.